Salix Pharmaceuticals announced Monday that federal regulators expect to have reviewed the company’s application for the drug Ruconest by July 16.
The Food and Drug Administration had originally planned to complete its review in April.
Raleigh-based Salix is developing the drug, a treatment for acute angioedema attacks, along with the Dutch drugmaker Pharming Group NV. Angioedema is a swelling just under the skin that is similar to hives.
Ruconest was one of the drugs being developed by the specialty drug company Santarus, which Salix acquired for $2.6 billion earlier this year.
Sign Up and Save
Get six months of free digital access to The News & Observer
Salix shares closed Monday at $108.26, up $2.89. The stock is up about 20 percent this year.